false
Hamburger Menu
Catalog
FDA Approval: Perioperative Pembrolizumab and KEYN ...
FDA Approval: Perioperative Pembrolizumab and KEYNOTE 671
Podcast | English | 2023 | 45 Min
Create Account
Cost
$0.00
Credit
No Credit Offered
IASLC Lung Cancer Considered Podcast
Host Dr. Narjust Florez leads a discussion about the data from the KEYNOTE 671 trial, presented at ASCO 2023 and ESMO 2023, that led to the first approval of the combination of pembrolizumab plus chemotherapy in the neoadjuvant and adjuvant setting.
Faculty
Podcast Hosts:
Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and Thoracic Medical Oncologist, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, USA
Podcast Guests:
Coral Olazagasti, MD, Assistant Professor, Sylvester Cancer Center, University of Miami, USA
Jonathan Spice, MD, PhD, FRCS, Division of Thoracic Surgery Director, MdGill University, Canada
×
FDA Approval: Perioperative Pembrolizumab and KEYNOTE 671 Course List
Login
User Login
Continue with Google
OR
Email
Password
Logging In…
Create Account
Forgot Password
×
Please select your language
1
English